Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 24, 2026
Alkermes PLC. (ALKS)
A forensic read on Alkermes PLC. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
14.5
Distress distance
Clean
Earnings quality
4
Forensic signals
110.1
P / E (ttm)
13.3%
ROE
$7.1B
Market cap
-5.2%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Alkermes PLC. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 14.5, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
353d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 275 to 353 FY2024→FY2025 (against cost of goods sold; inventory +8% vs -20% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
+19.7%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +19.7% relative to their own average in FY2025 — scaled by NOA itself, not by total assets, which is what the Forensic Screens card's own accrual row divides by. Accruals are building faster than is comfortable — part of profit is sitting in the balance sheet rather than turning to cash. A cash-flow measure on the same base disagrees: reported earnings ran behind operating cash by 21% of net operating assets, against an accruals ratio of 19.7%. The two are computed differently: the accruals ratio is the change in net operating assets over average net operating assets, while the cash-flow figure is net income less operating cash flow over that same average. Read them as two results, not one.
13.5%
FY2025
Return on invested capital.Return on invested capital is 13.5% in the latest fiscal year and slipping across FY2023–FY2025 from 32%. The capital base behind it cannot be compared across FY2023–FY2025: short-term debt and long-term debt are tagged in one of those two fiscal years and not the other, and an untagged line enters this calculation as zero, so any change in the base would be a change in what the filer tagged.
-0.3%/yr
FY2023–FY2025
Share count.Diluted share count changed -1% over the last 2 years to FY2025 (-0.3%/yr). Roughly flat — the count is neither shrinking nor growing meaningfully. Per-share value isn't being meaningfully helped or hurt by the count.
Key fundamentals
Latest Revenue$1.48B
Revenue Growth YoY-5.2%
Revenue CAGR (2yr)-5.8%
Net Margin16.4%
Free Cash Flow$480.3M
Return on Equity13.3%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Alkermes PLC.'s actual 10-K/10-Q/8-K filings?